 | Repotrectinib, sold under the brand name Augtyro, is an anti-cancer medication used for the treatment of non-small cell lung cancer. It is taken by mouth... 8 KB (421 words) - 13:19, 16 January 2024 |
 | price), helping to boost its complement of cancer drugs, specifically repotrectinib. That same month, the company announced it would be investing $180m... 91 KB (7,411 words) - 15:28, 29 April 2024 |
Infigratinib, Larotrectinib (NTRK), Pemigatinib (FGFR), Pralsetinib, Repotrectinib (ROS1, TRK, ALK), Selpercatinib (VEGFR, FGFR), Vandetanib (VEGFR, EGFR)... 12 KB (741 words) - 18:39, 6 May 2024 |
repaglinide (INN) Repan reparixin (USAN) repifermin (INN) repirinast (INN) repotrectinib (INN) repromicin (INN) Repronex reproterol (INN) Requip Resa Resaid... 6 KB (330 words) - 22:05, 20 March 2024 |
 | for treatment of TrkA-, TrkB-, TrkC-, ROS1- and ALK-positive NSCLC) Repotrectinib (TPX-0005, Turning Point Therapeutics) Belizatinib (TSR-011, Tesaro)... 17 KB (1,951 words) - 10:39, 25 January 2024 |
Infigratinib, Larotrectinib (NTRK), Pemigatinib (FGFR), Pralsetinib, Repotrectinib (ROS1, TRK, ALK), Selpercatinib (VEGFR, FGFR), Vandetanib (VEGFR, EGFR)... 12 KB (758 words) - 23:46, 14 March 2024 |